Serotonin transporter and serotonin receptors

Area of Science:

• Cardiovascular Research
• Pulmonary Medicine
• Pharmacology

Background:

• Pulmonary artery hypertension (PAH) pathogenesis involves pulmonary artery smooth muscle cell (PA-SMC) proliferation, with the primary defect remaining unclear.
• The serotonin (5-HT) hypothesis links PAH to 5-HT, supported by associations with anorexigenic drugs and selective 5-HT reuptake inhibitors.
• Serotonin acts as a vasoconstrictor and mitogen for PA-SMCs, mediated by the 5-HT transporter (5-HTT) and receptors.

Purpose of the Study:

• To investigate the role of the serotonin pathway in the proliferation of pulmonary artery smooth muscle cells (PA-SMC) in pulmonary artery hypertension (PAH).
• To explore the potential of targeting the serotonin pathway for novel therapeutic strategies in PAH.

Main Methods:

• Analysis of lung tissues from PAH patients to assess 5-HT transporter (5-HTT) expression.
• Assessment of the proliferative response of isolated PA-SMCs to 5-HT.
• Review of existing literature on the serotonin hypothesis and its implications in PAH.

Main Results:

• PAH lung tissues exhibit increased 5-HTT expression.
• Isolated PA-SMCs show an enhanced proliferative response to 5-HT.
• 5-HTT-overexpressing mice develop spontaneous pulmonary hypertension (PH).
• A 5-HTT gene polymorphism is associated with PH severity in chronic lung disease patients.

Conclusions:

• The serotonin pathway, particularly 5-HTT-mediated PA-SMC proliferation, is implicated in PAH pathogenesis.
• Inhibiting 5-HTT and 5-HT2B receptors shows promise in experimental PH models.
• Targeting 5-HTT for PA-SMC proliferation warrants investigation as a potential PAH treatment, though clinical efficacy in humans requires further study.